U.S. Markets close in 5 hrs 7 mins

S&P 500
4,130.87
+2.88(+0.07%)
Dow 30
33,603.55
-141.85(-0.42%)
Nasdaq
13,946.67
+96.67(+0.70%)

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

1.4400+0.0200 (+1.41%)

As of 10:53AM EDT. Market open.

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	1.4200
Open	1.4100
Bid	1.4300 x 28000
Ask	1.4400 x 21500
Day's Range	1.4100 - 1.4400
52 Week Range	1.0100 - 2.4000
Volume	430,076
Avg. Volume	3,993,953

Market Cap	458.685M
Beta (5Y Monthly)	1.16
PE Ratio (TTM)	N/A
EPS (TTM)	-0.2790
Earnings Date	Mar 11, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

All

Research Reports

$Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis$
Business Wire
Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in IMpactMF, the Phase 3 clinical trial evaluating imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
- $Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma$
  Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
  GlobeNewswire
- Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
  GlobeNewswire
Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
Motley Fool
Why Geron Corporation Stock Is Falling Today
Shares of clinical-stage biopharmaceutical company Geron Corporation (NASDAQ: GERN) are dropping sharply on Friday following the company's release of its fourth-quarter and full-year 2020 financial results, as well as some important clinical updates. As of 11:43 a.m. EST, Geron's stock was down by 8.7% after falling by as much as 10.1% earlier in the day. For its 2020 fourth quarter, ending on Dec. 31, Geron reported revenue (from license fees and royalties) of $50,000, compared to the revenue of $171,000 it had recorded during the prior-year quarter.